Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Nov 7, 2020Study 218 compares 18 mg and 14 mg starting doses of LENVIMA plus 5 mg everolimus in patients with clear-cell RCC following prior anti-angiogenic therapy, with prior anti-PD-1/PD-L1 therapy permittedEisai announced results from Study 218, a Phase 2 trial comparing the safety and efficacy of two different starting doses (18 mg versus 14 mg once daily) of LENVIMA, an orally available multiple...
- Nov 5, 2020Data includes an oral presentation on results from a Phase 2 trial evaluating starting doses of LENVIMA in combination with everolimus (LEN+EVE)
Eisai will present seven abstracts at the International Kidney Cancer Symposium (IKCS) 2020 from November 6-7, 2020. New investigational data from Study 218, a Phase 2 trial evaluating the safety...
-
Sep 20, 2020New Results Include Findings From the Phase 2 LEAP-004 Trial Showing an ORR of 21.4% in Patients With Unresectable or Advanced Melanoma Who Had Previously Progressed on an Anti-PD-1/PD-L1 Therapy
KENILWORTH, N.J., and WOODCLIFF LAKE, N.J., Sept. 20, 2020 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced new investigational data from two...
-
Sep 10, 2020Data to include key findings from the LEAP (LEnvatinib And Pembrolizumab) clinical trial program evaluating the combination across multiple cancers including melanoma, non-small cell lung cancer (NSCLC) and six new tumor types
Eisai will present two late breakers and 10 e-posters at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 from September 19-21, 2020. Notable data from ongoing LEAP clinical...
- Aug 11, 2020
Eisai Inc. announced today the topline results from Study 211, a Phase 2 trial evaluating the efficacy and safety of LENVIMA, an orally available multiple receptor tyrosine kinase inhibitor...